Entities

Harrison Wu is a principal in WI Harper’s Beijing office, focused on information technology, intelligent manufacturing and energy. Before venture investing he worked in business alliances and project management at China Mobile, business development at Hundsun, cloud research at Intel and product management at Shanda. He holds an international MBA associated with MIT Sloan and Tsinghua and a bachelor’s degree from the University of Electronic Science and Technology of China.

Kelvin Sun is a partner in the current WI Harper team directory. His individual biography describes technology investment and operating experience in semiconductors, telecommunications and enterprise IT, with interests in AI, augmented and virtual reality, robotics, blockchain and IoT. He previously led business development and technical marketing and worked at Ericsson on mobile technology. He studied information technology and management information systems at Rensselaer Polytechnic Institute.

Earl Yu is a WI Harper principal investing in healthcare management, robotics, manufacturing, data, enterprise software and AI. Earlier roles included technology, marketing and management at China Unicom, as well as work at Hong Yuan Securities and SDIC Fund. He holds an MBA from Peking University and a bachelor’s degree from Southwestern University of Finance and Economics.

Joyce Lee is a principal in WI Harper’s Taipei office, focused on healthcare, consumer and enterprise technology investments and portfolio support. She previously covered healthcare and finance as an equity analyst at Yuanta and later invested in drug development at Diamond BioFund. She studied political science and economics and earned an MBA in international financial management at National Cheng Kung University. She is distinct from the Uncork Capital finance professional with the same name.

Vincent Gao is a principal at WI Harper and a partner of its Luxin Fund. He focuses on advanced technologies, semiconductors, next-generation information technology and intelligent manufacturing. He joined WI Harper in2014 after investment work at Tuspark and technical management at Cisco. He holds an MBA from Tsinghua University and an engineering degree from Shanghai Jiao Tong University.

Phoebe Wang is a WI Harper partner based in Beijing, focused on advanced technology and new energy. Her biography describes investments in CloudBrain, Neuracle, Airwing and other businesses. Before joining the firm, she worked in product, marketing, online games and publishing strategy at Kingsoft. She holds an MBA from Tsinghua University and an engineering degree from Dalian Maritime University.

Edward Liu is published in the current WI Harper directory as managing partner. He supports investment sourcing, seed initiatives, fundraising and portfolio companies, and the individual biography identifies his management of Alibaba Taiwan Entrepreneurs Fund II. Earlier roles included China operations at The Piacente Group, investor relations at Xinhua Sports and Linktone, and venture banking at Silicon Valley Bank. He studied finance and marketing at the University of San Diego and holds an MBA from Shanghai Jiao Tong University.

Jeremy Tan is listed in EDBI’s current public directory as Investment Associate in Fund-of-Funds. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Kenneth Teo is listed in EDBI’s current public directory as Senior Principal in International Operations. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Liting Goh is listed in EDBI’s current public directory as Investment Associate in Fund-of-Funds. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Sean Peng is a senior partner in WI Harper’s Taipei office, focused on operations, portfolio support and investment opportunities in Taiwan and Beijing. He previously led Greater China investments at H&Q Asia Pacific and held senior roles at Fortune Venture Investment Group. Earlier he worked in engineering and Asian marketing at LSI Logic. He holds an EMBA from Peking University, an MBA from Santa Clara University and an electrical engineering master’s from UT Austin.

Wilson Wu is a managing partner at WI Harper Group. He previously worked in cybersecurity and invests across technology stages. The current primary biography names board responsibilities at Flexcompute, FusionSight, AINekko, RWDC, Alpha Ring and Avaamo. He studied finance, information systems and economics at the University of Virginia, accountancy at Notre Dame, business at Tsinghua and management at MIT. Its USD1.3B AUM statement describes the platform, not a newly closed fund.

Winnie Hsu is a partner in WI Harper’s Taipei office. Her investment interests include communications, wireless technology, digital media, software and technology applications. She also supports portfolio operations and business development. Her current biography identifies portfolio work involving Senhwa, iStaging and Appier among other companies. She holds a finance degree from the University of Adelaide.

Charles Wu is a senior partner at WI Harper, which he joined in2015 after executive and investment leadership at IBM. His earlier roles included vice president and managing director, founding management of the IBM China Investment Fund, and leadership in software and e-business. He studied finance at the University of Houston and completed executive education in venture capital, private equity and joint ventures.

Crystalbel Foo is listed in EDBI’s current public directory as Associate Principal in Fund-of-Funds. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Victor Gan is listed in EDBI’s current public directory as Associate Principal in Fund-of-Funds. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Kenny Ng is listed in EDBI’s current public directory as Associate Principal in Early-stage. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Peter Liu, also identified in SEC filings as Pete Yeau-Hwan Liu, is the founder and chairman of WI Harper Group. His career focuses on venture investments across the United States and Asia and building cross-border business relationships. He has supported technology companies through investment, strategic networks and access to Greater China. The current firm biography describes international civic and business affiliations; these relationships are distinct from an investment by their institutions.

Roy Chua is listed in EDBI’s current public directory as Investment Manager in Early-stage. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Yigong Wang is WI Harper’s chief operations officer for its Beijing office. He previously spent19 years at China Ocean Shipping Company, serving in research, technology and shipbuilding leadership, and earlier worked at Tianjin University. He holds a mechanical engineering doctorate from Brunel University and a master’s degree in engineering from Tianjin University.

Jodie Foo is listed in EDBI’s current public directory as Associate Principal in Early-stage. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Nathanael Fheng is listed in EDBI’s current public directory as Principal in Early-stage. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Derrick Xu is listed in EDBI’s current public directory as Investment Manager in Next Gen Hardware. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Jonathan Trisno is listed in EDBI’s current public directory as Investment Manager in Next Gen Hardware. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Siah Sin Cheng is listed in EDBI’s current public directory as Senior Principal in Next Gen Hardware. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Tae Yoon Song is listed in EDBI’s current public directory as Investment Associate in Green & Bio Economy. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Estella Goh is listed in EDBI’s current public directory as Investment Manager in Green & Bio Economy. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Harold Au is listed in EDBI’s current public directory as Senior Principal in Green & Bio Economy. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Brian Liau is listed in EDBI’s current public directory as Investment Manager in Healthcare. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Christine Giam is EDBI’s Partner leading Green and Bio Economy, Next Generation Hardware, Early-stage and Fund-of-Funds investments. Her current four-sector scope supersedes older archived sector cards. Her biography describes helping build EDB’s New Ventures division, earlier GIC private-equity and Advanced MedTech roles, and biomedical-engineering studies at the National University of Singapore.

Andre Lai is listed in EDBI’s current public directory as Investment Manager in Healthcare. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Tan Kuan Boone is listed in EDBI’s current public directory as Associate Principal in Healthcare. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Andrew Krishna Ekaputra is listed in EDBI’s current public directory as Senior Principal in Healthcare. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Jolene Ooi is EDBI’s Healthcare Partner investing in biotechnology, precision medicine and therapeutic modalities. Her earlier A*STAR research involved gene editing and stem-cell models of Huntington disease. Her qualifications include National University of Singapore life sciences and a Cambridge/Wellcome Sanger molecular-biology doctorate. Published portfolio responsibilities are institutional affiliations rather than personal checks.

Gerald Teng is listed in EDBI’s current public directory as Investment Associate in Digital Economy. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Jia Ming Ang is listed in EDBI’s current public directory as Investment Manager in Digital Economy. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Michelle Lim is listed in EDBI’s current public directory as Associate Principal in Digital Economy. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Lim Rong Yang is listed in EDBI’s current public directory as Senior Principal in Digital Economy. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Tang Chung Hang is listed in EDBI’s current public directory as Senior Principal in Digital Economy. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Charmaine Kng is EDBI’s Partner for Digital Economy, returning to the firm in mid-2023. Her background includes founding-team work at EvolutionX, DBS venture-debt leadership and earlier EDBI growth-equity investing. EvolutionX is a separate fund, not an EDBI managed vehicle. She holds Nanyang Technological University aerospace-engineering and Imperial College London finance degrees.

Yeung Chia Li is EDBI’s Senior Partner overseeing Digital Economy investments. His published biography describes ICT and fund-of-funds investing, market expansion and portfolio value creation. Earlier experience includes Motorola hardware and RF engineering; his qualifications include Nanyang Technological University engineering and a National University of Singapore MBA.

Paul Ng is EDBI’s Chief Executive Officer, appointed on 1 February 2023, and SG Growth Capital’s Chief Corporate Officer. The government directory identifies him as Paul Ng Tat Peng. He joined EDBI in 2010, following investment work at GIC and IT infrastructure work at PSA. He holds a CFA charter, a Singapore Management University wealth-management master’s degree and a National University of Singapore electrical-engineering degree. SGGC parent CEO Choo Heng Tong holds a separate role.

Scion Life Sciences is a New York biotechnology venture investor and company builder affiliated with Petrichor. It creates therapeutics companies around academic, industry and internally developed discoveries, combining long-term financing with scientific and operating support from initial incubation through clinical development and potential commercialization. Its internal Scion Innovations hub designs and tests protein therapeutics, antibodies and other biologics, supporting drug-discovery and company-formation work. The firm backs medicines across serious diseases rather than a neuroscience-only mandate; its team includes experienced developers of neurological and neuromuscular therapies.

Therapeutics investor and company builder with prior roles at Medicxi and Apple Tree Partners.

Abhishek Datta is published in the roster of Scion Innovations, the firm’s internal therapeutic discovery and company-incubation hub.

Amanda Rodrigues Mariano is published in the roster of Scion Innovations, the firm’s internal therapeutic discovery and company-incubation hub.

Protein-engineering and structural-biology specialist who founded Marengo Therapeutics and led biologics technologies at Novartis.

Anumeha Rajvanshi is published in the roster of Scion Innovations, the firm’s internal therapeutic discovery and company-incubation hub.

Ariella Golbin is published in the roster of Scion Innovations, the firm’s internal therapeutic discovery and company-incubation hub.

Capital-formation professional leading marketing, development and fundraising for Petrichor and its affiliate Scion.

Douglas Sauter is published in the roster of Scion Innovations, the firm’s internal therapeutic discovery and company-incubation hub.

Finance professional shared with Petrichor, with prior controller experience at Colbeck Capital Management and DiMaio Ahmad Capital.

Biochemist and investor who completed fellowships at Scion, Flagship Pioneering and Vida Ventures.

Hugh Chen holds the source-published role of Associate within RA Capital Management’s Healthcare group. The individual directory reports joining in2026; a precise appointment day is not available. Published academic qualifications: PhD. Universities identified in the own biography: UC San Diego, Harvard University. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Biotechnology company builder who was Stoke Therapeutics’ founding CEO and subsequently its COO and CBO.

Healthcare investment operations executive who also serves as Petrichor’s Chief Compliance Officer; previously co-founded Pavadi and Symphony Capital.

Khikmet Sadykov is published in the roster of Scion Innovations, the firm’s internal therapeutic discovery and company-incubation hub.

Biopharmaceutical company builder and R&D executive, currently CEO of Scion portfolio company Flux Therapeutics.

Leticia Angelini is published in the roster of Scion Innovations, the firm’s internal therapeutic discovery and company-incubation hub.

Business developer at Eclore Actuators. Represented the company at the International Industrial Fair Kobe on September 3–4, 2026, presenting its polymer-folding and interface products to local manufacturers and integrators.

Joined Eclore Actuators’ commercial team in an apprenticeship announced September 1, 2026. Trains alongside Alexandre Lainé on the company’s polymer-folding technology and supports its presence in the French market.

Biotechnology scientist and entrepreneur with experience building nucleic-acid medicines, including prior leadership at Ascidian and Dyne Therapeutics.

Sakshi Thakre is published in the roster of Scion Innovations, the firm’s internal therapeutic discovery and company-incubation hub.

Immunologist, company builder and therapeutics investor; previously a partner at Apple Tree Partners.

Steve O’Neil is published in the roster of Scion Innovations, the firm’s internal therapeutic discovery and company-incubation hub.

Founder of Petrichor and Scion, with healthcare investment experience at OrbiMed and Fortress.

Todd Borland is published in the roster of Scion Innovations, the firm’s internal therapeutic discovery and company-incubation hub.

Physician-scientist and former Scion fellow with immunotherapy research experience at Caltech.

Zhaohui Zhang is Executive Vice President, China Chief Operating Officer at WuXi AppTec. One of our co-founders, entrepreneur, formerly Senior Vice President of WuXi AppTec, Vice President of Domestic Marketing of WuXi AppTec. EMBA from China Europe International Business School.

Steve Qing Yang is Co-CEO at WuXi AppTec. A pharmaceutical industry leader recognized for building R&D and service capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships in US, Europe, China and other Asian and emerging markets. Before joining WuXi AppTec, Dr. Yang was Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, and served as Vice President and Head of Asia R&D at Pfizer and as Executive Director and head of Pfizer's global R&D strategic management group. Dr. Yang received his Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco. Current legal filing publishes full name Steve Qing Yang.

Minzhang Chen is Co-CEO at WuXi AppTec. Over 20 years of experience in pharmaceutical development and manufacturing. Played important roles in R&D and commercialization of multiple innovative drugs for global launches. Awarded by The Medicine Maker's 2019 & 2020 Power List as one of the global top inspirational medicine makers driving the industry forward. Formerly Director of Technical Operations at Vertex. Bachelor's degree in Chemistry from Peking University and Ph.D. in Organic Chemistry from the University of Minnesota.

Cognigy develops enterprise software for AI agents that automate customer service over phone, chat and messaging. Its Cognigy.AI platform combines conversational and generative AI, grounded company knowledge, agent orchestration, voice connectivity, integrations with contact-centre and business systems, analytics, and assistance for human service agents. Enterprises use its low-code tools to design, operate and evaluate customer-facing AI workflows. Founded in 2016 in Düsseldorf, Cognigy was acquired by NiCE in September 2025 and now operates as NiCE Cognigy. Eurazeo Growth Fund IV’s 2024 investment is a historical, subsequently exited holding.

Eclore Actuators is a Nantes-based industrial deep-technology company designing and manufacturing polymer components with an automated folding process inspired by origami. Its commercial products include lightweight protective bellows and protection kits for SCARA industrial robots, flat protective bellows and related accessories that shield moving equipment in demanding operating environments. It also develops active polymer components such as actuators, ejectors and grippers, with lifting tubes and level or angle compensators shown as upcoming product ranges. Applications include industrial robotics, defence, aerospace, food production and pharmaceuticals. The company develops its own production and R&D machinery and supplies standard and custom components.

Sales employee named by Eclore in its own current trade-show posts, including its 2026 ESA Space Solutions stand. Own 2023 announcement records his initial arrival as an apprentice; current role is qualified by newer issuer posts rather than assuming apprenticeship continues.

Co-founder and software engineer specialising in scalable, containerised systems on Kubernetes. Holds a BSc in Software Engineering. Previously built software for medical, automotive, gaming and social-media applications; helped establish Cognigy engineering processes and product delivery. The same current directory also labels his full-bio section VP Engineering.

Contact-centre and unified-communications executive with experience as CEO, CFO, and in business development, partnerships, strategy and corporate development at AVAYA, Intradiem and AVST. Works with Cognigy leadership on strategic priorities, partnerships and business processes.

Customer-service automation and business-strategy executive. Has held leadership roles at NiCE since 2015, including vice president and general manager of CXone Moxie and director of business development. Previously a consultant at Shaldor and an Israeli Air Force officer. Holds an MBA and a BA from Tel Aviv University.

Finance and digital-business executive with experience at Bertelsmann Multimedia, comdirect and AOL, followed by strategy consulting in digital transformation and M&A. Previously led a gaming startup finance function through an exit and served as CFO and CEO of Content Fleet. Holds a degree in economics and game theory.

Co-founded Cognigy in 2016 with Sascha Poggemann and Benjamin Mayr. Leads AI innovation and platform strategy at NiCE Cognigy following its 2025 acquisition. Previously held leadership positions at SAP and Sitecore, building Sitecore operations in Australia and New Zealand and leading global sales.

Founded Eclore Actuators in 2019 after engineering studies. Experience with folding applied to space propulsion during an exchange in Seoul inspired an automated polymer-folding machine and the company’s industrial technology.

Technology entrepreneur focused on human-machine interaction in enterprise applications. Before co-founding Cognigy, led technical development at iExergy, including technology scouting, product development, and IoT and cloud projects. Holds an MSc in Information Technology and is an executive board member of Bitkom.

Leads a team of UX designers, value engineers and agentic-AI specialists helping enterprises deploy and scale AI for customer experience. An early Cognigy employee who helped build Professional Services and Presales. Background in enterprise integration architecture and management consulting.

Wildcat Capital Management’s current directory identifies Marie Maser as Executive Assistant. Marie Maser joined Wildcat in 2019 and is currently an Executive Assistant on the Public Investments and Real Estate Teams. Marie previously worked at Pegasus Capital Advisors as an Executive Assistant. Marie grew up in Philadelphia, PA and graduated from the Fox School of Business at Temple University with a BA in Business Management and Legal Studies.

Wildcat Capital Management’s current directory identifies Magdalena O'Brien as Executive Assistant. Magdalena O’Brien joined Wildcat in 2018 and is currently an Executive Assistant on the Private Investments Team. Magdalena previously worked at Quentec Asset Management as an Operations Associate / Executive Assistant. Magdalena grew up in Maspeth, NY and graduated from Brooklyn College with a BBA, Concentration in Finance and Investments.

Wildcat Capital Management’s current directory identifies Debra Bergin as Director of Office Administration. Debra Bergin joined Wildcat in 2011 and is currently the Director of Office Administration and Assistant to the President/CIO. Debra previously worked at Neuberger Berman as an assistant to the Managing Director/COO.

Wildcat Capital Management’s current directory identifies Sherri Conn as Chief Financial Officer. Sherri previously held various management positions at TPG Capital and worked at Ernst & Young in the audit group. Sherri grew up in Fort Worth, TX and graduated from Texas A&M University with a BA in Accounting. Her published CFO position is specifically with Wildcat Partner Holdings, LP, a related investment partnership; inclusion in the manager directory does not change that legal employer.

Wildcat Capital Management’s current directory identifies Connor Fox as Associate. Connor Fox joined Wildcat in 2024 and is an Associate on the Private Investments Team. Prior to Wildcat, Connor worked at Copley Equity Partners, a lower-middle market private equity firm focused on growth and structured equity investments across sectors. Connor grew up in Boulder, CO and graduated from Brown University with a BA in Political Science.

Wildcat Capital Management’s current directory identifies Rahul Khambete as Senior Associate. Rahul Khambete joined Wildcat in 2026 and is a Senior Associate on the Private Investments Team. Rahul previously worked at Berkshire Partners where he focused on private equity transactions across industrials and business services sectors. Prior to Berkshire Partners, Rahul was with Greenhill & Co.

Wildcat Capital Management’s current directory identifies Utkarsh Sonkiya as Vice President. Utkarsh Sonkiya joined Wildcat in 2026 and is a Vice President on the Private Investments Team. Prior to Wildcat, Utkarsh worked at Apollo Global Management where he focused on private equity transactions across industries and L Catterton, a consumer growth equity fund. Utkarsh grew up in New York, NY and graduated from the University of Notre Dame with a BBA in Finance, a BA in Economics and a minor in Chinese.

Wildcat Capital Management’s current directory identifies Ross Barlow as Vice President. Ross Barlow joined Wildcat in 2022 and is a Vice President on the Private Investments Team. Prior to Wildcat, Ross worked at CI Capital Partners, a middle-market private equity firm specializing in buy-and-build investments across business and consumer services sectors. Prior to CI Capital Partners, Ross was at Jefferies in the Technology Investment Banking Group.

Wildcat Capital Management’s current directory identifies Samantha Tutelman as Director of Business Development. Samantha Tutelman joined Wildcat in 2025 and is the Director of Business Development where she is responsible for sourcing and evaluating investment opportunities, fundraising, and investor relations. Prior to Wildcat, Samantha helped start Bessemer’s first-time private equity strategy, BVP Forge, an investment firm focused on growth-oriented, self-sustaining software-enabled and services businesses. Prior to BVP Forge, Samantha was at PSG, a growth-stage software focused investment firm, and Bank of America in the Technology Investment Banking Group.

Wildcat Capital Management’s current directory identifies Alan Xie as Principal. Alan Xie joined Wildcat in 2016 and is a Principal on the Private Investments Team. Prior to Wildcat, Alan worked at Ares Management where he focused on private equity transactions and structured equity investments. Alan grew up in Leavenworth, KS and Troy, MI and graduated with high distinction from the University of Michigan's Stephen M.

Wildcat Capital Management’s current directory identifies Jeff Messer as Managing Director. Jeff Messer joined Wildcat in 2016 and is a Managing Director on the Private Investments Team. Prior to Wildcat, Jeff worked at Vestar Capital Partners, a middle-market private equity firm specializing in management buyouts and growth capital investments. Prior to Vestar, Jeff worked at Morgan Stanley in the Global Power & Utility Group.

Wildcat Capital Management’s current directory identifies Brian Rosenblatt as Managing Director, General Counsel & Chief Operating Officer. Brian Rosenblatt joined Wildcat in 2018 and is a Managing Director and the General Counsel and Chief Operating Officer. Prior to Wildcat, Brian was General Counsel at Sculptor Capital Management (formerly known as Och-Ziff), a global alternative asset manager. Prior to Sculptor, Brian worked as an attorney focused on mergers and acquisition and private equity at Vinson & Elkins LLP, an international law firm, where he represented private equity funds, hedge funds, family offices, and other public and private companies.

Wildcat Capital Management’s current directory identifies George Stone as Managing Director, Head of Real Estate. George Stone joined Wildcat in 2018 and is a Managing Director and the Head of Real Estate Investments. George previously was the Co-founder and CEO at Kalyx Development, the first private cannabis REIT, and has worked at or owned a variety of real estate focused companies, including SKL Partners, Julia B. George grew up in Scarsdale, NY and graduated from the University of Michigan with Honors with a BA in Film & Theatre Management.

Wildcat Capital Management’s current directory identifies Drew Tarlow as Managing Director, Head of Private Investments. Drew Tarlow joined Wildcat in 2013 and is a Managing Director and the Head of Private Investments. Prior to Wildcat, Drew worked at Pegasus Capital Advisors, a middle-market private equity fund, Wood Creek Capital Management, a special situations fund, and Medley Global Advisors, a macro policy advisory firm. Drew currently sits on the boards of Express Wash Concepts, Club Car Wash, Rapid Express Car Wash, Glia Technologies, Groff Tractor & Equipment, Hubble Contacts, Walters Hospitality, Who Brew, and previously served on the board or as a board observer at Skillz, US Mobile, and Eloquii.

Published XSeed director ofmarketing withexperience inglobalbranding, communications andeventmanagement acrossindustries. Her2019 own-firm biography supports a historicalrole, without assuming currentfulltimeemployment.

Published XSeed fellowemeritus withHarvard governmentstudies andearlierBridgewater chief-of-staff experience. Herfirmbiography describes StanfordMBAstudies andAnheuserBuschInBev acceleratorwork; thesearehistorical ratherthanassertedcurrentstudentstatus.

Published XSeed director ofadministration withadministrative andoperations experience supportingmultiplebusinesses. The2019 directory is retainedas the verified historicalpublicroster; currentemployment is notindependentlyconfirmed.

Lilt co-founder andCEO withStanford computerscience doctoral work in natural-languageprocessing; published as anXSeed fellowemeritus inits2019 directory. He is distinct fromTSVC investorSpencerGreene andOrbit teammemberSpencerGreen.

Published XSeed fellowemeritus with product-marketing experience spanning advertising, analytics andmachinelearning. The2019 biography referencesUnity andFacebook andStanfordbusinessstudies; outsidecurrenttitles are notasserted.

Published XSeed fellowemeritus and EloquentLabs co-founder with Stanford doctoral research in natural-languageprocessing. The2019 directory reflects his historical fellowship ratherthancurrentmanageremployment.

Published XSeed EIRemeritus with experience inonlineadvertising, ecommerce andSaaS atGoogle andArtTechnologyGroup. Hismanageraffiliation is retainedas2019historicalnetworkcontext.

Published XSeed EIRemeritus with operations andmarketing experience. Its2019 biography citesCocoTerra, Rapt, BetterPlace andSIPX; currentcontinuation atthoseoutsidecompanies is not inferred.

Published XSeed EIRemeritus with product-management experience atGoogle, Docker, Heroku, Box, Amazon andPayPal. Thisis the2019 historicalexpert network, notacurrentmanagerstaffclaim.

Published XSeed EIRemeritus with entrepreneurial growth experience. Its2019 biography describesunitQgrowth responsibilities andUSCalumni status, retained as source-publishedhistoricalcontext.

Published historical XSeed executive-in-residence whoseoperatingcareer includesIntel andFacebook. He wrote BecomingFacebook andcontributed managerarticles ontechnology andleadership. The2019 directory locateshim in its emeritusnetwork.

Published XSeed EIRemeritus with experience commercializing SaaSmarketing andanalytics businesses. The2019 biography citesSimilarWeb andGetSmartify; thesehistoricalcareerreferences are notassertedcurrentexternalemployment.

Published XSeed EIRemeritus with marketing experience atVaporIO, Mesosphere, Heroku andDesk.com. Hislistedoutsidepositions are thefirm’s2019 publishedcareercontext, not independently confirmedcurrentroles.

Published historical XSeed fellow with nonprofit andconsulting experience, including EverybodyDanceNow, Spark andBridgespan. Her2019 biography describes Stanfordbusiness andHarvardpublicadministration studies; those are time-qualified ratherthanassertedcurrent.

Published XSeed EIRemeritus with earlier healthcare-energyconsumerbusiness leadership, including ChooseEnergy, ModCloth andWalmart.com. The2019 directory places her among formerresidents; noactivefulltimeXSeed appointment is claimed.

Published historical XSeed fellow whose2019 biography describes Stanford MBA/computerscience studies following CPUdesign engineering atIntel. No currentstudentstatus ormanager employment is inferred.

Published XSeed executive-in-residence with product-leadership experience inSiliconValley, including JPMorganChase, Bloomspot andYahoo. His2019 affiliation is preserved as a historicaloperating-expert role.

Published XSeed entrepreneur-in-residence whose career includes ecommerce, delivery experience andmarketing atAmazon, ShipHawk, Pixlee, Photobucket andShutterfly. The manager’s2019 directory is historical anddoesnotestablish a currentfulltimemanager role.

Published XSeed special adviser on complex technology andscience. The2019 biography also describes teaching atStanford’s designschool and aMohrDavidow general-partner position; these are source-publishedhistorical affiliations, notcurrentemployment assertions.

Published XSeed venture partner and former chief executive ofWovenSystems, withBroadcom operating experience. His manager work emphasized enterprise-software transformation. Thisrole is sourced to the2019 directory and subsequentcurrentcontinuation is unverified.

Company builder and published XSeed partner with Stanford business-school anddesign-school affiliations andanengineering background atUBC. His2019 manager affiliation is preserved as historical, without asserting that every current Enya/Boba role is employment atXSeed.

Published XSeed partner who joined inJune2016 after operating and corporate-strategy experience atSurveyMonkey andYahoo. His investment background emphasizes market, geographic andplatform risk. The2019 manager roster is historical; currentcontinuation is not independently established.

XSeed general partner and Stanford management lecturer whose investment interests include technology-driven business operations. His career includes GE Security, Intel and founding WeaveInnovations, acquired byKodak. Stanford’s current primary profile also identifies him as a Piva venture partner.

Founder of XSeed in2006, focused on AI, autonomous systems and technical intersections with life sciences and materials. He previously worked with MohrDavidow and co-founded the BerkeleyRoundtable on theInternationalEconomy; he holds Princeton, Berkeley andHarvard degrees. His current general-partner role is confirmed by his February2026 SEC signature.

XSeed Capital, also styled X/Seed Capital, is the U.S. early-stage venture manager legally named X/Seed Management Company LLC. Its February25,2026 SEC Form ADV identifies CRD160343 and exempt-reporting-adviser file802-75135, with a San Francisco principal office. This is distinct from Singapore SEEDS Capital, Danish Seed Capital and the unrelated XSEED Education business. Michael Borrus founded XSeed in2006; its current homepage describes support for entrepreneurs building category-leading high-growth companies. Primary firm biographies and portfolio announcements establish investments across AI, natural-language processing, autonomous systems, enterprise software, life sciences and materials informatics. Examples include Lilt, Lex Machina, Citrine Informatics, Artisan Bio, Enya, Biota, AtScale and robotics-related businesses. Portfolio affiliation, company acquisitions and board seats are kept distinct from verified financing transactions. The current SEC filing confirms founding general partner Borrus, while Stanford’s current profile corroborates Robert Siegel’s general-partner affiliation. The full own-firm2019 roster is preserved with explicit historical qualifications: six investment/advisory professionals, two operating residents, two fellows, twelve emeritus network members and two operations professionals. Their historical university and outside-company titles are not asserted as current2026 employment. Detailed firm team pages are currently unavailable, so the archived source and authentic native named portraits are retained rather than inventing a current exhaustive private directory. The2026 adviser filing reports three separately constituted Delaware partnerships: X/Seed Capital LP, X/Seed Capital II LP and XSeed Capital S LP, each with its own GP. Their gross assets, historical AUM, targets and unverified database fund-close headlines are not newly raised cash. FundII’s September2011 FormD reports zero sold against anUSD80M target; final close sizes remain undisclosed here. Actual Lilt2020SeriesB and2022SeriesC buyer attributions are verified against issuer primary releases, with existing financing IDs and protected historical graph preserved during a separately owned bounded correction.

David Griffin is named as an Omega Healthcare Investors corporate strategy and investor-relations contact. No extended career biography or authentic portrait is supplied by the official contact directory. He is kept distinct from the pre-existing namesake sourced from Arize, whose identity as the same person is unproven.

NeuroVision Imaging, Inc. is a Sacramento healthcare technology company founded in2010, historically operating as NeuroVision Imaging LLC. Its current integrated platform combines BrainHealth Clinic telehealth cognitive care, Afina retinal imaging and Duritect blood-based biomarker development for neurodegenerative diseases. Afina is a cloud-based AI imaging pathway intended to identify retinal disease signatures and support treatment-safety monitoring; the company explicitly labels certain components investigational or under development and not FDA-cleared or approved. FDA records confirm Afina Release1.1 received510(k) clearance K181501 on November2,2018 for retinal-image importing, processing, display and autofluorescence measurement. The cleared software reports measurements for clinician interpretation and does not provide a specific clinical diagnosis; this does not establish clearance of an Alzheimer’s diagnostic claim or the company’s broader current biomarker platform. Research feasibility, clinical-service availability and device marketing authorisation are distinct. NeuroVision announced the acquisition of Durin Life Sciences on May12,2026, combining blood-biomarker programmes for Alzheimer’s, Parkinson’s and ALS with its retinal imaging and patient-care infrastructure; transaction consideration is undisclosed. CEO and co-founder Steven Verdooner continues to lead the combined company, and Durin majority owner Ric Edelman joined its board. Its current corporate website publishes seven directors; its own BrainHealth service publishes eleven operational leaders/staff and eight scientific advisers, with overlapping people reconciled. Historical scientific founders include Keith L. Black, Maya Koronyo-Hamaoui and Yosef Koronyo, associated with Cedars-Sinai retinal-amyloid research; their historical appointments are not assumed current executive jobs. A2016 Series B announcement confirms a USD5million lead investment from Wildcat Capital Management while reserving part of a USD10million financing for strategic investors. AMay2,2018 Series C completed an initial USD11.2million close toward USD15million; no additional USD15million cash event is inferred. Current primary investor materials also identify Labcorp, Gates Ventures, Tiny Orange Capital and Gaston Capital without round dates or allocations. The Alzheimer’s Drug Discovery Foundation reports two closed diagnostics projects awarded in2020 and2021; their funding instruments and payment timing require qualification.

Annamarie Robinson is SR DIRECTOR OF FINANCE associated with NeuroVision Imaging’s BrainHealth programme. With over 32 years of accounting experience in the medical, retail, and manufacturing industries, Annamarie oversees NeuroVision Imaging’s financial operations and HR functions, including policies, compliance, payroll, benefits, and employee support. Her expertise supports sound financial management, operational accountability, and employee well-being across the company.

Brian Knauss is Product Manager associated with NeuroVision Imaging’s BrainHealth programme. Two decades of experience bringing products to life as an Engineer and Product Manager at high tech companies.  Has found his professional home taking startups 0-to-1 as a founder and product leader.

Dawn Lenakakis is Clinical Staff Manager associated with NeuroVision Imaging’s BrainHealth programme. Dawn brings over 20 years of experience in the medical field, with a strong focus on clinical research in cognitive neurology. She’s passionate about helping patients through every step of their care, acting as a trusted connection between them and their doctors. She combines strong clinical knowledge with genuine commitment to compassionate, well-coordinated care.

Douglas Galasko is a scientific adviser to NeuroVision Imaging’s BrainHealth programme. Dr. Galasko is a Neurologist (specialist with Brain Health and Memory Disorders program) and Professor of Neurosciences at UCSD Health, as well as Associate Director of the UC San Diego Shiley-Marcos Alzheimer's Disease Research Center.

Eugeen Vanmechelen is a scientific adviser to NeuroVision Imaging’s BrainHealth programme. With over 30 years’ research experiences, Dr. Vanmechelen is founder and CSO at ADX, which researches and quantifies biomarkers for neurodegenerative disease. He is also involved in multiple international projects, including the EU Miriade Project, which is working to discover and clinically validate biomarkers for dementia.

Gary Root is DIRECTOR OF ENGINEERING associated with NeuroVision Imaging’s BrainHealth programme. Has over 10 years of software development experience in the medical imaging and device industry at previous companies including Philips Healthcare. Passionate about bridging the gap between innovative ideas and product  implementation by applying the principles of software and data science to solve problems.

Glenn Walthall is a NeuroVision Imaging director and Managing Partner of Gaston Capital. He has approximately30years of venture-capital, investment-banking, banking and consulting experience, with board and chairman appointments in healthcare and technology businesses. He holds a BS and MBA from Virginia Tech and is based in Charlotte, North Carolina.

Greg Cole is a scientific adviser to NeuroVision Imaging’s BrainHealth programme. Professor of Medicine and Neurology at UCLA Medical Center, Dr. Cole is also Associate Director of the UCLA Alzheimer's Center, and Associate Director for Research at the Geriatric Research, Education and Clinical Center for the Greater Los Angeles Veterans Administration System.

Hamad Rehman is SOFTWARE ENGINEER associated with NeuroVision Imaging’s BrainHealth programme. Hamad is a professional software developer with 10 years of experience specializing in Python and the MEAN Stack. He focuses on building fast, scalable, and secure web applications, with expertise spanning both backend development and full stack architecture. Hamad also brings strong experience in DevOps, supporting efficient deployment and operations for modern web platforms.

Josef Tamory is Sr Clinical Applications Specialist associated with NeuroVision Imaging’s BrainHealth programme. Josef has more than 20 years of experience in Ophthalmology, including work with private practices, hospitals, and academic and research institutions. He has served as an instructor and speaker at prestigious Annual Review Programs for the Georgetown University Review Courses, as well as JCAHPO/ATPO AAO Annual meetings since 2008.

Keith L. Black, MD, is a scientific co-founder of NeuroVision Imaging and was documented as its chairman in2017–2018. A Cedars-Sinai neurosurgeon, he helped develop retinal-amyloid imaging research with Maya Koronyo-Hamaoui. His current institution describes work in blood–brain barriers, targeted drug delivery, optical imaging and Alzheimer’s disease. He is absent from the current company board directory; historical chairmanship is not assumed current.

Larry Ward is a scientific adviser to NeuroVision Imaging’s BrainHealth programme. With over 20 years’ biotech experience at companies including AMRAD, Virax, CRC for Mental Health, and Medicines Development for Global Health, Dr. Ward is currently COO at Medicines Development for Global Health, as well as Head of Business Development at CRC for Mental Health and Australian Imaging, Biomarker and Lifestyle Study of Ageing.

Leonard A. Potter is a NeuroVision Imaging director and founder, president and chief investment officer of Wildcat Capital Management. He founded Wildcat in2011 after private-equity leadership roles at Soros Fund Management. NeuroVision’s2016 financing announcement appointed him to its board; the current issuer directory confirms he remains a director. Wildcat Capital Management’s current directory identifies Len Potter as Chief Executive Officer, Chief Investment Officer. Len previously was a Managing Director and co-head of the private equity group at Soros Fund Management. Prior to Soros, Len served as a Partner and Managing Director of Alpine Consolidated LLC and Capstone Partners LLC, each a private merchant bank, and as an attorney specializing in mergers, acquisitions and corporate finance at Morgan, Lewis & Bockius LLP and Willkie, Farr & Gallagher LLP. Len also co-founded and serves as a Senior Managing Director of Vida Ventures, a next-generation life sciences investment fund.

Leyla Anderson is VP Biomarker Development associated with NeuroVision Imaging’s BrainHealth programme. Has 20 years of experience in medical research, infectious diseases and immunology, biomarker development, diagnostics, and laboratory medicine. *Diplomate, American Board of Medical Laboratory Immunology (CLIA-approved)

Mark Selna, MD, is a NeuroVision Imaging director and member of its BrainHealth scientific advisory board. He has more than30years of health-system, health-plan and medical-practice experience, previously serving as President and CEO of Quartz. His current published biography also identifies co-founding an AI company supporting health-system operations and outcomes.

Maya Koronyo-Hamaoui is a NeuroVision Imaging scientific co-founder, inventor and researcher, identified in its2017 clinical research announcement. She is a Cedars-Sinai professor investigating Alzheimer’s disease, retinal pathology and neuroimmunology. She obtained a PhD in psychiatric genetics at Tel Aviv University and completed neuroimmunology postdoctoral training at the Weizmann Institute. Her founding affiliation does not establish current employment in NeuroVision’s operational team.

Mieko Chambers is VP Operations associated with NeuroVision Imaging’s BrainHealth programme. Has over 10 years of experience in academic and medical device settings. Experience in a variety of research compliance areas, including clinical trials and human subject research, as well as leading quality and regulatory teams. Mieko has directed several clinical trials and collaborated with many mainstream large pharmaceutical companies.

René Chaze is a director of NeuroVision Imaging and a Partner at Tiny Orange Capital. His experience spans strategy, operations and finance across technology and life-science investments. He previously served as CFO, COO and head of mergers and acquisitions at Edelman Financial Services and was an Ernst & Young partner. NeuroVision’s current own board biography identifies René Chaze as Partner at Tiny Orange Capital, focusing on high-growth technology including blockchain, digital assets and life sciences. He brings more than 35 years of strategy, operations and finance experience, previously CFO, COO and head of M&A at Edelman Financial Services and an Ernst & Young partner. Board and manager roles do not imply a personal investment. René Chaze is named a Durin director in the issuer’s2019–2025 SEC disclosures. His separate current NeuroVision director and Tiny Orange Capital partner affiliations remain preserved. Board service does not alone prove personal investment; any NJEDA-reported investment requires distinct ticket/date qualification.

Ric Edelman is a NeuroVision Imaging director, joining its board following the May2026 acquisition of Durin Life Sciences, where he was the majority owner. He founded Edelman Financial Services and is an author and educator in personal finance. The board appointment does not establish a separate new cash investment in NeuroVision. Ric Edelman identifies Tiny Orange Capital as his family office in his December 17, 2024 issuer announcement, through which he provides strategic advisory services and expands investments in fintech, exponential technology and digital assets. His NeuroVision board role is independent of this family-office affiliation. Formal Tiny Orange corporate officer title, legal ownership percentage and appointment dates are not disclosed. Ric Edelman is identified as Durin Life Sciences’ majority owner in the May12,2026 acquisition announcement and joins the combined NeuroVision board. The release does not disclose a personal cash investment amount, acquisition consideration or continuing independent target-company officer role.

Richard Travis Wilkes is Chief Medical Officer associated with NeuroVision Imaging’s BrainHealth programme. Dr. Wilkes is a board-certified physician with an extensive background in biopharma and laboratory innovation. He serves on several medical advisory boards while also maintaining a clinical practice focused on applying cutting-edge technology to personalized patient care.

Roy Ervin Twyman, MD, is a NeuroVision Imaging director and a member of its BrainHealth scientific advisory board. His neuroscience drug-development experience includes serving as senior vice president and Alzheimer’s disease-area leader at Janssen Pharmaceutical Research & Development. He is a board-certified neurologist and psychiatrist with prior academic and regulatory-advisory experience.

Steven Verdooner is CEO, director and co-founder of NeuroVision Imaging. He previously co-founded and led Ophthalmic Imaging Systems, developing ophthalmic imaging and informatics products, and served as executive vice president at OPKO Health. His career spans more than30years in ophthalmology, neurology and medical devices. The May2026 acquisition announcement confirms he continues as CEO of the combined NeuroVision and Durin enterprise. Steven Verdooner is named CEO of the combined NeuroVision business following its announced acquisition of Durin Life Sciences on May12,2026. This relationship records leadership of the combined operating business; it does not assert an undisclosed separate statutory CEO appointment at Durin.

Traci Chu is VP CRM associated with NeuroVision Imaging’s BrainHealth programme. Traci is an ecommerce, CRM, and performance marketer with over 30 years' experience at lifestyle, marketing analytics, and health/med-tech companies. Though she spent her early years at behemoths Mattel and Williams-Sonoma, she loves launching new products that impact lives.

Yosef Koronyo is a scientific founding member and inventor of NeuroVision Imaging, as documented by its2017 retinal-imaging research announcement. He is a Cedars-Sinai researcher developing noninvasive retinal imaging methods. His institutional biography lists natural-sciences and molecular-microbiology/biotechnology study at Tel Aviv University. Current issuer employment and an accessible authentic individual portrait remain unverified.

Mesenkia Therapeutics is a Swedish-Japanese preclinical biotechnology company developing KITAIbodies®, modular single-domain antibodies directed at HVEM, a signaling pathway implicated in glioblastoma and other cancers. Its lead program seeks to treat aggressive glioblastoma by combining HVEM-targeting antibodies with technologies that transport therapeutics across the blood-brain barrier. The company develops drug candidates through its proprietary antibody platform and research collaborations; its products are in preclinical development.

StemSight is a Finnish biotechnology company developing off-the-shelf regenerative cell therapies for severe corneal blindness. Its technology combines corneal cells manufactured from induced pluripotent stem cells with functional biomaterials for tissue regeneration and cell delivery. Its first program targets limbal stem cell deficiency; the company is advancing preclinical studies and manufacturing toward clinical development, and aims to reduce reliance on donated corneal tissue.

Andrew Dorsey is named by Omega Healthcare Investors as a corporate strategy and investor-relations contact. The official contact page publishes this capacity but does not supply an individually named portrait or extended professional biography.

Burke Whitman is an Omega Healthcare Investors director andColmarHoldings chief executive. His earlier healthcare leadership includesHealthManagementAssociates,TriadHospitals andDeerfieldHealthcare. He also served as aUSMarineCorps reserve and active-duty officer and holds other corporate and nonprofit governance roles.

Stephen Plavin is an Omega Healthcare Investors director with commercial real-estate lending and debt-investment experience. He was aBlackstone senior managing director until hisJuly2025retirement. His currentOmega board role is distinct from that formeremployment.

Kevin Jacobs is an Omega Healthcare Investors director andHilton’s chief financial officer and president for global development. His background covers corporate finance, hospitality real estate, development and acquisitions, with earlier roles atFairmontRaffles andHostHotels.

Barbara Hill is an Omega Healthcare Investors director and aNexPhaseCapital operating partner. Her healthcare leadership includes managed behavioral health, pharmacy services and health plans, includingValueOptions andExpressScripts. Her board experience includes medical technology businesses.

Lisa Egbuonu-Davis is an Omega Healthcare Investors director with medical, public-health and healthcare strategy experience. Her earlier work included medical innovation atDanaher-related diagnostic businesses and patient-centered programs atSanofi, following research and outcomes work atPfizer. She also serves on healthcare company boards.

Craig Callen chairs Omega Healthcare Investors’ board. His experience includes healthcare corporate strategy atAetna, investment banking atCreditSuisse andDonaldsonLufkinJenrette and advisingCrestviewPartners. He also serves in real-estate and philanthropic governance roles.

Kapila Anand is an Omega Healthcare Investors director with accounting, audit and real-estate governance experience. She previously served as aKPMGpartner and senior advisor and has held listed-company board and audit-committee roles, includingElanco. She is aCPA.

Megan Krull is Omega Healthcare Investors’ senior vice president for data, intelligence and government relations. She oversees reimbursement, regulatory and legislative work and develops and implementsOmega’s artificial-intelligence strategy. Her background includes asset management atOmega andCapitalSource; she studied business atGeorgetown andlaw atAmericanUniversity.

Lucas Golem is Omega Healthcare Investors’ vice president and chief accounting officer, appointed inAugust2026. His earlier roles included Omega financial-reporting leadership, accounting atWillScot andAlgecoScotsman and auditing atDeloitte. He is aCPA and studied accounting atLoyolaUniversityMaryland.

Gail Makode is Omega Healthcare Investors’ chief legal officer and general counsel. Her earlier work included legal and compliance leadership atIESHoldings andMBIA and securities and transaction work atDeutscheBank andClearyGottlieb. She studied atJohnsHopkins andYaleLawSchool.

Neal Ballew became Omega Healthcare Investors’ chief financial officer inAugust2026 after serving as chief accounting officer. Before joiningOmega in2020, he worked inEY’s real-estate and hospitality audit practice and technical accounting. He earned accounting degrees atBrighamYoungUniversity.

Vikas Gupta is Omega Healthcare Investors’ chief investment officer, responsible for investment origination, underwriting, structuring and portfolio management. His earlier healthcare real-estate work included CapitalSourceFinance. He studied finance atGeorgeWashingtonUniversity.

Matthew Gourmand became Omega Healthcare Investors’ president and chief executive officer and joined its board onOctober1,2026. His earlier Omega work covered investor relations and corporate strategy. Previously he managed equity portfolios and worked in equity research and auditing; he studied law atUniversityCollegeLondon and holds professional accounting andCFAqualifications.

Diplom-Ingenieur Friedrich Papst is an Austrian industrial executive and investor, explicitly named as a PIUR IMAGING co-investor by its closed2026 SeriesB crowdfunding campaign. His own ANDRITZ2014 annualreport and2022 corporatehistory establish his mechanicalengineering studies at TechnicalUniversityGraz, joiningANDRITZ1979, and formerexecutiveboard career. ANDRITZ’s own announcement records his retirementMarch31,2015 aftermorethan35years; a currentSchuler corporatepage lists him as a supervisoryboardmember and formerANDRITZexecutive. Austria’s officialregister identifies him as a managingdirector of dpaequity&consultingGmbH FN445755y sinceJanuary19,2016, and PIUR’s currentregister separately lists dpaequity as a corporate shareholder. The campaign’s literalindividualname is retained without asserting that he personally paid a specific currentticket or replacing it with an inferred dpa legalpayer. This is distinct from the unrelated youngerHeineken namesake and unrelated deceasedPapst. His authenticportrait is the company’s named2014 annualreport photograph; its age does not imply currentANDRITZ employment.

Professor Dr Heinz-Walter Grosse (German spelling Große) is a published PIUR IMAGING co-investor and a current individually named shareholder in the Austrian company register, enteredSeptember9,2026; the register date is not a verified cash-closing date. His current own CHBGroup biography identifies him as Chairman of its AdvisoryBoard and establishes the exact formerB.Braun identity: financeemployee1978, CFO2005, vicechair2009, CEO/managementboardchairApril2011–March2019, and Aesculap supervisorychair2018–March2023. He is not described as the currentB.Braun CEO or currentAesculapchair. The closed2026 PIURSeriesB crowdfunding campaign explicitly lists ProfDrHeinz-WalterGrosse as a co-investor, but does not disclose a personal new ticket, instrument or commitment day. This attribution remains a source-qualified campaign roster participation; his ownership or advisory positions are not converted into additional cash transactions.

James Weis is published by the Nest.Bio platform as Partner; CEO Nest.Bio Labs and Hatch.Bio Labs (affiliates). He is also founding CEO of Hatch.Bio Labs and a co-founder of MIT Alumni Angels of Boston, whose current institutional biography independently distinguishes the venture partner role from laboratory leadership.

Johannes Herzog is investment analyst at HPVC (Hasso Plattner Venture Capital), the venture-investment platform formerly HPI Ventures and legally operated by HPI Seed Fund GmbH in Potsdam. The current native manager page publishes the Investment Analyst role, superseding the older HPI Ventures website’s Software Engineer title. No unverified education, earlier employment or exact appointment day is inferred.

Ananda Siml is creative & marketing lead at HPVC (Hasso Plattner Venture Capital), the venture-investment platform formerly HPI Ventures and legally operated by HPI Seed Fund GmbH in Potsdam. The current official manager publishes this named role and original portrait. Its team operates alongside the Hasso Plattner Institute ecosystem, supporting early-stage enterprise technology, AI and digital-health founders. Detailed education, earlier employment and appointment dates are not published in the retrieved native roster.

Jeremy Simon is investment analyst at HPVC (Hasso Plattner Venture Capital), the venture-investment platform formerly HPI Ventures and legally operated by HPI Seed Fund GmbH in Potsdam. The current official manager publishes this named role and original portrait. Its team operates alongside the Hasso Plattner Institute ecosystem, supporting early-stage enterprise technology, AI and digital-health founders. Detailed education, earlier employment and appointment dates are not published in the retrieved native roster.

Joy Srinivas-Vargas is published by the Nest.Bio platform as Site Manager, Hatch.Bio Labs (affiliate directory). The public role is distinct from any unreported personal equity investment; laboratory affiliate capacities are explicitly qualified where applicable.

Trevor Schuck is published by the Nest.Bio platform as Business Development Director, Hatch.Bio Labs (affiliate directory). The public role is distinct from any unreported personal equity investment; laboratory affiliate capacities are explicitly qualified where applicable.

Omega Healthcare Investors, Inc. is a publicly traded healthcare real estate investment trust (NYSE:OHI), founded in1992, providing property and financing capital to long-term-care operators. Its portfolio focuses on skilled nursing, assisted living and care homes, predominantly through triple-net leases and increasingly RIDEA arrangements. It is a corporate REIT rather than a venture-capital fund manager or an external LP fund. Matthew Gourmand became president and chief executive officer and joined the board effectiveOctober1,2026; Neal Ballew became CFO effectiveAugust1,2026. The current own directory identifies six executives and an eight-member board. The company’s published data and government-relations leadership also develops and implements its artificial-intelligence strategy. Its strategic healthcare technology investments include Neteera’s contactless patient monitoring, explicitly identified by the issuer’s2023SeriesB announcement. Property leases, operator relationships, credit commitments and care-provider commercial partnerships are not automatically company equity checks. The listed corporation is distinct from subsidiaries such as guarantor OHI Healthcare Properties Limited Partnership and from unrelated Omega Funds or Project Omega. Corporate debt/equity issuances are kept separate from nonexistent external LP fund closes; undrawn credit-facility limits and portfolio asset values are excluded from cash raised.

Hannah Looks is venture partner at HPVC (Hasso Plattner Venture Capital), the venture-investment platform formerly HPI Ventures and legally operated by HPI Seed Fund GmbH in Potsdam. Her own manager’s welcome announcement describes prior impact venture-capital work with B2B healthtech, climate and techbio founders and prior work with Michael Mansfeld in the German Bundestag.

Hingge Hsu is published by the Nest.Bio platform as Partner. The public role is distinct from any unreported personal equity investment; laboratory affiliate capacities are explicitly qualified where applicable.

Steven Landau is published by the Nest.Bio platform as Venture Partner. The public role is distinct from any unreported personal equity investment; laboratory affiliate capacities are explicitly qualified where applicable.

Jens Schmidt-Sceery is managing director at HPVC (Hasso Plattner Venture Capital), the venture-investment platform formerly HPI Ventures and legally operated by HPI Seed Fund GmbH in Potsdam. The current legal imprint confirms him as a managing director of HPI Seed Fund GmbH, and the official rebrand announcement also quotes him under the title Managing Partner.

Cheryl Cui is published by the Nest.Bio platform as Partner. She is a founding partner of Nest.Bio Ventures and co-founder of Bota Biosciences; her primary2020 MIT Technology Review award biography describes medical engineering and medical physics training at Harvard-MIT.

Lorena Dai is published by the Nest.Bio platform as Investment. The public role is distinct from any unreported personal equity investment; laboratory affiliate capacities are explicitly qualified where applicable.

Rebecca Liess is executive assistant at HPVC (Hasso Plattner Venture Capital), the venture-investment platform formerly HPI Ventures and legally operated by HPI Seed Fund GmbH in Potsdam. The current native team spells her name Rebecca Liess; the managing director’s own rebrand post uses Rebecca Ließ. These published orthographic variants identify the same named executive assistant.

Samantha Clark is published by the Nest.Bio platform as Office Operations Coordinator, Hatch.Bio Labs (affiliate directory). The public role is distinct from any unreported personal equity investment; laboratory affiliate capacities are explicitly qualified where applicable.

Ruven Looks is investment analyst at HPVC (Hasso Plattner Venture Capital), the venture-investment platform formerly HPI Ventures and legally operated by HPI Seed Fund GmbH in Potsdam. The current official manager publishes this named role and original portrait. Its team operates alongside the Hasso Plattner Institute ecosystem, supporting early-stage enterprise technology, AI and digital-health founders. Detailed education, earlier employment and appointment dates are not published in the retrieved native roster.

Xi Chen is published by the Nest.Bio platform as Venture Partner. He is also the co-founder of RootPath, a biotechnology company, and helped establish Nest.Bio’s venture creation activity, as described in VIB’s institutional speaker biography.

Michael Mansfeld is principal and head of product at HPVC (Hasso Plattner Venture Capital), the venture-investment platform formerly HPI Ventures and legally operated by HPI Seed Fund GmbH in Potsdam. The current official manager publishes this named role and original portrait. Its team operates alongside the Hasso Plattner Institute ecosystem, supporting early-stage enterprise technology, AI and digital-health founders. Detailed education, earlier employment and appointment dates are not published in the retrieved native roster.

Nest.Bio Ventures is a life-sciences venture creation and investment platform established in 2017, focused on translating scientific and technological breakthroughs into biotechnology companies across North America and Asia. Its own investment approach combines early company creation, scientific and operating support, active investing, and collaboration with founders. Relevant backing includes Engine Biosciences’ AI/ML-driven drug discovery, Astrocyte Pharmaceuticals’ investigational neuroprotective medicines, and synthetic-biology and cell-therapy ventures. The website is shared with Nest.Bio Labs, whose laboratory doors opened in2018 and whose next generation is Hatch.Bio Labs; laboratory residency, business incubation and lab-affiliate employment do not individually establish an equity investment. Its current shared public directory names12 people: four partners, three venture partners, one adviser, one investment professional, and three explicitly identified Hatch.Bio lab operating staff. Daphne Teo is additionally CEO of NSG BioLabs; James Weis leads the affiliated laboratory platforms. The genuine current shared Nest.Bio Labs logo is retained with that brand qualification; it is not fabricated as a separate Ventures wordmark. SEC-filed resTORbio investor documents identify Nestbio WO VI Holding LP as a subscribing legal vehicle, with Adena Partners GP I LLC as general partner and Cheryl Hao Cui signing as member. A separate Adena Partners I LP Form D identifies the same GP and Adena Partners Management LLC, signed by Hao Cui, but this shared management evidence does not prove every Nest.Bio investment was subscribed through that fund. The June8,2017 Form D reported zero sold, no first sale, and an indefinite offering; no closed fund corpus is inferred. The specific subscriber vehicle for Engine’s2018 and2021 financings remains unpublished. Laboratory alumni market value, jobs created and resident counts are not fund sizes or deployed cash. No separately verified completed fund closing has been found.

Biovance Capital Partners is a Portuguese life-sciences venture capital manager investing in early-stage biopharmaceutical companies across Europe, especially Southern Europe. It backs seed and Series A drug-development businesses across therapeutic areas and modalities, evaluating preclinical evidence, intellectual property and routes to clinical development. The team works with scientific founders and co-investors to build companies and advance potential treatments. Its industry partners include BIAL, whose expertise in epilepsy, Parkinson’s disease and rare diseases complements the fund’s broad therapeutic mandate; the fund retains independent investment decisions.

Claris Ventures is an Italian venture capital manager that invests in and creates biotechnology companies developing new medicines. From Turin, it supports businesses from company formation and preclinical research through early clinical development, combining scientific assessment, financing, governance and operating support. Its portfolio spans neurology, oncology, metabolic disease, respiratory disease and other therapeutic areas; neuroscience investments include IAMA Therapeutics’ work on neuronal chloride regulation and serious central nervous system disorders. The legal manager is Claris Ventures SGR S.p.A., VAT 12116290011.

Accounting professional supporting administrative operations and financial processes.

Claris co-founder with venture-investment, product-management and technology-transfer experience. Ciro Spedaliere serves as Board member at Sibylla Biotech. Co-founded Claris Ventures. His background spans venture investing and product management, with management-engineering education at Turin Polytechnic and executive venture training at Berkeley. IAG publishes Ciro Spedaliere as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Founding Partner. Life Science Co-fondatore di Claris Ventures, primo fondo italiano di venture capital specializzato in biotech. In precedenza ha lavorato in altri fondi di VC e come product manager nel settore dell’innovazione.

Entrepreneur and independent director with international-business-development and investment-platform experience.

Scientist and investor with molecular-biotechnology, neuro-oncology and neurodevelopment research experience.

Biomedical engineer supporting scientific and strategic assessment of early-stage biotechnology investments.

Immunology scientist and business-development professional with pharmaceutical and biotechnology experience.

Biovance scientific adviser; the published roster identifies his outside role as a chemical-biology professor at the University of Cambridge.

Biovance scientific adviser and consultant at Symbiokraft in Spain.

Biovance scientific adviser; the published roster identifies her outside role as Chief Business Officer at Biognosys in Switzerland.

Financial executive advising on private-equity investment and business development.

Finance adviser with investment-banking, private-equity and impact-investing experience. Manilo Marocco is identified by Claris Ventures as a senior adviser with approximately three decades of investment banking and private equity experience, including capital markets, fund management and seed/impact initiatives. An archived2019 Tessellis biography documents earlier Salomon Brothers, Springwater and Stirling Square work. These professional affiliations do not establish his exact MMP title or a personal Restorative investment.

Biovance scientific adviser and strategic-technology consultant at Bioconsulting in the United Kingdom.

Pharmaceutical physician and drug developer supporting early-stage company creation, with RNA-therapeutics and infectious-disease experience.

Engineer and investment professional with biotech operations and neural-network data-analysis experience.

Biomedical engineer and venture investor who co-founded Claris Ventures.

Finance professional overseeing the firm’s accounting, administration and financial analysis.

Biovance scientific adviser; the published roster identifies his outside role as Global Head of R&D at Sumitomo Pharma in Switzerland.

Pharmaceutical-development adviser with oncology, rare-disease and corporate-venture experience. Roberto De Ponti is a 3B Future Health Fund general partner; his own biography also identifies a managing-director role. His background covers pharmaceutical research, manufacturing, licensing and business development, including prior Helsinn corporate development work. He holds a PharmD and is an EU Qualified Person. Existing Claris Ventures advisory affiliation is preserved.

Frank Pawlitschek is managing director at HPVC (Hasso Plattner Venture Capital), the venture-investment platform formerly HPI Ventures and legally operated by HPI Seed Fund GmbH in Potsdam. He also directs HPI Engine, the institute’s entrepreneurship center. An official HPI biography describes law degrees and a doctorate from Mainz and Auckland, a decade specializing in M&A and technology law, and co-founding EV charging company ubitricity in 2008 before its 2021 exit.

Patrick Markus Aisher, commonly published as Patrick Aisher, is chairman of Kinled Holding. His current Danube Labs biography describes life-sciences investing since1997, with biomedical device, biopharmaceutical and healthcare-service investments, and directorships at Aleva Neurotherapeutics and PreComb Therapeutics. It describes sourcing university spin-outs across Europe and the United States; its portfolio and exit counts are self-reported career figures. A primary 2012 SEC corporate biography gives his full legal name, British-Austrian background, university study in Canada and the United Kingdom, engineering investments since1992 and a directorship at Hong Kong Kinled Holding Ltd. Current manager sources identify chairman; an undated page title referring to CEO does not establish a second current role or an appointment date. Mountain Labs AG named Patrick Aisher as a principal/key person in its 2023 SECA yearbook entry. The 2024 entry names only Thomas de Camborne Lucy, so Aisher’s exact current Mountain Labs role and term are not assumed.

HPVC (Hasso Plattner Venture Capital) is the Potsdam-based early-stage software investor formerly branded HPI Ventures, operated by HPI Seed Fund GmbH, Amtsgericht Potsdam HRB 28361. Its current official imprint names Frank Pawlitschek and Jens Schmidt-Sceery as managing directors. Its September 2026 rebrand announcement expressly confirms continuity of the same team, fund and investment thesis. The historical HPI Seed Fund was already investing before the HPI Ventures brand, including the actual February 2023 Memodio financing; the older HPI Ventures about page’s 2024 founding statement is a brand-era claim and is not treated as the legal entity’s incorporation date. Situated next to the Hasso Plattner Institute, HPVC backs European pre-seed and seed businesses in enterprise technology, AI, digital health and cybersecurity, and offers founder support and enterprise introductions through HPVC Tailwind. Current native portfolio examples include clinical-documentation company voize, dementia digital-therapy developer Memodio, ultrasound-AI company Thinksono, digital-health company Praxipal, pathogen sequencing-software company Seqstant and enterprise-AI companies Qorelo and Zeit AI. The Hasso Plattner Institute ecosystem affiliation does not make the institute a second cash buyer, and no merger with similarly named Hasso Plattner Ventures managers is inferred. Retrieved primary sources do not disclose a verified external LP fund close or corpus; indicative investment tickets and accelerator offers are not fund sizes or evidence of completed company proceeds. The complete current public roster has nine named staff with authentic own-published portraits. The former HPI website’s software-engineer role for Johannes Herzog is superseded by the current native investment-analyst title; Carl von Bechtolsheim is not included in the current roster and no departure date is inferred.

Kinled Holding Ltd is the Hong Kong family-owned investment holding company identified as a direct investor in Nanoflex Robotics. Companies House corporate-member filings identify KINLED HOLDING LIMITED as a Hong Kong limited company, registration 1693695, with the same Wilson House address as its own website. The Kinled investment brand traces its establishment to 1980 in its submitted SECA directory, while Aisher family business antecedents date to the 1920s; 1980 is the reported brand establishment, not a verified incorporation date for the present Hong Kong entity. Patrick Aisher is its publicly identified chairman. Kinled invests in advanced medical devices, robotics, precision medicine, drug discovery, neuromodulation, digital health, software and fintech, both directly and through independently managed partner funds and incubators. Its website reports 175 portfolio investments including indirect fund positions; this is not a count of independently verified direct cash checks. The website is operated by Kinled Austria GmbH and describes multiple group affiliates, which are not assumed to be interchangeable legal buyers. Current chairman commentary rejects the family-office label, although the investment group is family-owned. Partner-fund combined AUM and portfolio counts are not final capital closes or the holding company’s own cash fundraising. The current public website names the chairman but publishes no comprehensive employee directory; historical SECA key-person affiliations are separately qualified.

Smart-city and emerging-technology attorney/adviser; NYC Starting Up and Venture Smarter co-founder and former White House/State Department experience. Published Neteera affiliation: Advisory Board Member (external adviser).

Coronary and structural interventional cardiology specialist and clinical researcher; external medical adviser, not employee. Published Neteera affiliation: Chairman, Medical Advisory Board (external adviser).

Raith Capital Management asset-management managing director/senior adviser, with structured finance and asset development experience. Exact middle initial retained. Published Neteera affiliation: Board Member.

Co-founder of Misfit, Elemental Machines, AgaMatrix and FireSpout; former Fossil connected-devices president and CTO. Published Neteera affiliation: Board Member.

Advanced Orthopaedics founder and New York orthopaedic surgeon; issuer identifies him as a Neteera founder and board member. Published Neteera affiliation: Co-founder; Board Member.

Former Ness Technologies CTO, dbMotion founder/chairman, Maayan Ventures CEO and Jerusalem Technology Investment CEO. Published Neteera affiliation: Chairman of the Board.

B2B marketing/communications leader; advertising journalism degree from University of Nebraska-Lincoln. Published Neteera affiliation: Marketing Manager, United States.

Digital-health and medical-device business-development leader. Ran is current primary directory spelling; Rani in older reports is not another person. Published Neteera affiliation: Vice President, Business Development, APAC & EMEA.

Semiconductor executive with high-speed communication and mixed-signal design experience; formerly MultiPhy VP R&D. Published Neteera affiliation: Chief Technology Officer.

CPA; joined2024 as global controller, now finance director. Financial reporting, audit, SOX and taxation experience. Published Neteera affiliation: Director of Finance.

AI and healthcare technology executive; Technion operational research MSc and experience leading AI, deep-learning, NLP and analytics R&D. Published Neteera affiliation: Vice President, Product.

Fractional customer-success leader; clinical leadership, healthcare delivery and digital-health experience. External/fractional status preserved. Published Neteera affiliation: Fractional Vice President, Customer Success.

Medical technology commercial executive; previously Fresenius heart/lung business global sales/marketing VP, Abiomed and Corindus marketing leader. Published Neteera affiliation: Chief Commercial Officer.

Current own directory names Jason Taylor, despite original portrait filename Jacob-Taylor. Former Panda Health chief growth officer with technology and healthcare sales leadership. Published Neteera affiliation: Chief Growth Officer.

Wenqing Zhou, professionally known as Sara Zhou, is a cross-border healthcare investment and advisory professional. The Swiss-Chinese Chamber of Commerce’s 2025 member interview describes her former role as a Cross-border Advisor at Mountain Labs and prior senior investment and advisory work at Intercontinental Capital and Shanghai Creation Investment. Her work connects healthcare companies and investors across China, Europe and the United States. The chamber records an MBA from INSEAD, a finance master’s degree from Case Western Reserve University and an economics bachelor’s degree from the University of International Business and Economics. Her Mountain Labs role is historical, despite her public LinkedIn headline still displaying the firm; exact start and end dates are undisclosed.

Dominique Peter is a Switzerland-based professional whose own public LinkedIn profile lists Mountain Labs as an affiliation. The firm’s public company page also lists Dominique Peter among its employees. The personal profile includes prior Swiss professional experience and investment-sector activity, but its publicly retrievable text does not disclose a precise Mountain Labs job title or appointment dates. Those details remain unknown; same-name professionals in other industries are not merged.

CPO since2020; prior Comold/Bluran Line CEO and Mobileye aftermarket product executive. Published Neteera affiliation: Chief Product Officer.

Fabio Blom is named as one of Mountain Labs AG’s three key people in its 2023 SECA yearbook entry. His own public professional profile identifies him with COFABA Investments AG. The Mountain Labs affiliation is retained as a dated published principal role; its 2024 directory entry no longer lists him, so a current Mountain Labs appointment is not asserted. This investment professional is distinct from the younger Amsterdam UMC neonatal researcher of the same name; that researcher’s biography and portrait are excluded.

Joined as COO in2025; prior COO and VP supply chain at STK Bio-AG and corporate Pacific operations director at Orbotech. Published Neteera affiliation: Chief Operations Officer.

Founder and CEO; formerly CEO of Mobileye’s aftermarket division, Telepath and ABSC. Published Neteera affiliation: Founder & Chief Executive Officer.

Neteera Technologies Ltd. is an Israeli medical-technology company developing contactless, radar-based remote patient monitoring. Its sub-terahertz micro-radar detects small bodily movements without cameras, microphones, wearables or attached skin sensors. The platform combines measured vital signs with AI-powered insights, baseline analytics and alerts for clinical care teams, including hospitals, nursing facilities and home monitoring. This is AI-enabled medical sensing and semiconductor deep technology; a brain-interface or standalone neurological diagnosis is not asserted. The FDA cleared its Class II 130H-Plus vital-sign monitoring sensor on February9,2024 under K231733 for spot and continuous heart-rate/respiration-rate measurement in adult patients and bed-exit information. The company reports European ClassIIa CE MDR certification in March2025. Clearance applies to the named device and intended use, not unrestricted approval of every analytics claim. Isaac Litman is founder and CEO. Its public directory names eleven executives/operators, four additional directors and two external advisers; fractional and advisory roles are qualified. Verified financing includes a March2020 Series A investment with unpublished amount/day, approximately USD13 million Series B closed April25,2023 and approximately USD6.7 million additional Series B extension closed October31,2023. The later USD19.7 million cumulative Series B figure is their combined total and is not another raise. Earlier secondary-only funding amounts conflict and are retained as research gaps. Historical Aescuvest platform checks are distinct from ACP Healthtech’s later manager portfolio association, which does not prove an additional priced round.

Thomas de Camborne Lucy, also professionally known as Tom de Lucy, is an entrepreneur and investor. Mountain Labs AG names him among its key people in the 2023 and 2024 SECA yearbooks. His current Bricksave biography identifies him as CEO and co-founder, with experience investing in early-stage businesses and building real-estate investment platforms. The SECA personal member directory retains his full professional name and contact identity. His Mountain Labs published principal role is source-dated; a complete live 2026 company directory was not available. The Kinled Holding Ltd manager-submitted SECA2023 directory also lists Thomas de Camborne Lucy as a key person. It supplies no exact role title or current term; this is a historical2023 affiliation, not a verified present appointment.

Mountain Labs AG is a Swiss early-stage incubator, direct investment platform and corporate-finance business based in Schönried, Saanen. Its published materials describe a group of direct investors and family offices supporting entrepreneurs from initial development through exit. The firm was established in 2021. Its investment interests include biotechnology, medical technology, life sciences, fintech, internet software, energy and environmental technology, with published geographic focus on Switzerland, Austria and the United Kingdom. Its direct neuroscience and deep-technology relevance includes a verified investment in Nanoflex Robotics, which develops magnetic robotic systems for neurovascular interventions, and a biotechnology investment in FluoSphera, a University of Geneva spin-off developing animal-free microphysiological systems for drug discovery. The 2023 Swiss Private Equity and Corporate Finance Association yearbook names Thomas de Camborne Lucy, Patrick Aisher and Fabio Blom; its 2024 edition names Thomas de Camborne Lucy. Additional public professional profiles identify Dominique Peter and former cross-border adviser Wenqing (Sara) Zhou. The firm operates a direct investment and incubation model; no publicly verified separate institutional fund closing or cash fundraising amount was found. Its own website returned an origin connection timeout during this audit, so the published roster and historical portfolio are qualified by their source dates rather than assumed to be a complete live 2026 directory. This Swiss investor is distinct from Mountain Partners, similarly named consulting and retreat businesses, and unrelated overseas Mountain Labs companies.

Wei Mingjian is listed in Seviora Capital’s current investment directory as Associate (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Jean Chew is listed in Seviora Capital’s current investment directory as Associate (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Li See Weng is listed in Seviora Capital’s current investment directory as Associate (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Ho Sheng Yung is listed in Seviora Capital’s current investment directory as Senior Associate (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Sam Chen is listed in Seviora Capital’s current investment directory as Manager (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Chew Jun Sheng is listed in Seviora Capital’s current investment directory as Manager (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Shaun Lim is listed in Seviora Capital’s current investment directory as Manager (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Phua Zai Jie is listed in Seviora Capital’s current investment directory as Manager (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Goh Qing Kai is listed in Seviora Capital’s current investment directory as Manager (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Faisal Ramlee is listed in Seviora Capital’s current investment directory as Manager (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Gideon Chan is listed in Seviora Capital’s current investment directory as Manager (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Kenneth Tong is listed in Seviora Capital’s current investment directory as Associate Director (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Kwok Lih is listed in Seviora Capital’s current investment directory as Director (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. He leads technology investment, with earlier semiconductor and technology experience at Intel and Infineon.

Jenessa Ho is listed in Seviora Capital’s current investment directory as Director (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Kenneth Wong is listed in Seviora Capital’s current investment directory as Director (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Khor Boon How is listed in Seviora Capital’s current investment directory as Head of India, Pavilion Capital Investments. The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Melissa Lin is listed in Seviora Capital’s current investment directory as Director (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. She is part of the healthcare investment team, with earlier research-enterprise coordination work at Singapore’s National Research Foundation.

Ng Shufei is listed in Seviora Capital’s current investment directory as Director (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Phillips Huang is listed in Seviora Capital’s current investment directory as Director (Pavilion Capital Investments team within Seviora Capital). The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. He leads the healthcare investment team and previously worked as an A*STAR scholar and Genome Institute of Singapore research fellow.

Professor Charles McCollum, the UniversityofManchester vascular surgeon, was a founder of PIUR IMAGING as disclosed in his own coauthored scientific publications. The Austrian official company register publishes him as a shareholder in an August29,2025 company notice. His vascular expertise includes carotid disease and cerebral perfusion research. These facts do not establish a current executive job, an exact new cash contribution or identity with the unrelated US insurance executive of the same name.

Ian Long is listed in Seviora Capital’s current investment directory as Head of Korea, Pavilion Capital Investments. The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Lloyd Lim is listed in Seviora Capital’s current investment directory as Head of China, Pavilion Capital Investments. The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Lee Yann Fang is listed in Seviora Capital’s current investment directory as Head of Japan, Pavilion Capital Investments. The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. Country coverage, qualifications and earlier experience are documented in the linked primary biography. Year-only joining dates remain qualified in source research without inventing a day.

Milad Mesri is PIUR IMAGING’s Head of Product in its March30,2026 signed DICOM statement. The issuer’s own2023 welcome announcement describes his MSc in physics and prior hands-on experience at SiemensHealthineers. His product role is distinct from an unrelated engineer with the same name in the UnitedKingdom.

Danny Wong is listed in Seviora Capital’s current investment directory as Head of Investment Group, Pavilion Capital Investments. The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. He oversees Pavilion investment activity, portfolio construction and platform initiatives, following senior investment-banking roles at Jefferies and Macquarie. He holds degrees from MIT Sloan and the National University of Singapore.

Milos Stojanovic reviewed PIUR IMAGING’s DICOM conformity statement as HeadofQM&RA and digitally signed it on March30,2026. The earlier2025 FDA submission names him QualityandRegulatoryAffairsManager. The newer primary title prevails; regulatory contact status does not constitute product approval beyond the specific FDA clearance.

Ong Lui Chun is listed in Seviora Capital’s current investment directory as Managing Director, Pavilion Capital Investments. The primary biography identifies prior Pavilion Capital employment and continuity into its current Asian private-equity platform after the 2026 amalgamation. She is a founding Pavilion professional from 2012 and leads investment strategy and portfolio management. Her earlier experience includes PwC deal advisory, Arthur Andersen and corporate development; she holds a Nanyang Technological University business degree and CFA/CVA qualifications.

Stefania Paperini prepared PIUR IMAGING’s current DICOM conformance statement as SoftwareEngineer and digitally signed it on March30,2026. The document supports an engineering role in the company’s ultrasound software interoperability work. A third-party seniority claim is not promoted to an official title.

Pavilion Capital is a Singapore-based private equity fund-of-funds and co-investment platform established in 2012 within the Temasek ecosystem. Its historic investment manager was Pavilion Capital International Pte. Ltd., with Pavilion Capital Holdings, its general partner and fund or investment subsidiaries legally distinct. The franchise invests across Asian markets, including innovative technology and healthcare, through fund commitments, direct investments, co-investments and secondaries. Pavilion Capital amalgamated into Seviora Capital in 2026 and continues as the Pavilion Capital Investments platform; the retained brand and published team distinguish it from other Seviora strategies. Founding CEO Tow Heng Tan retired on 31 March 2026, while Danny Wong heads the Pavilion investment group and Ong Lui Chun leads its investment team. Its verified AI-related investments include Engine Biosciences and Schrödinger. The unrelated New York Pavilion Capital Partners at pavilioncapital.com, Pavilion Energy and Pavilion Data are separate businesses. Seviora group AUM and Pavilion historic balance-sheet assets are not recorded as fund-close proceeds.

Melanie Krauss is named PIUR IMAGING Head of Marketing in its July9,2025 growth-financing release. Her own public profile identifies PIUR IMAGING. This is a dated marketing affiliation rather than an asserted complete2026 employee roster; no departure day or new executive position is guessed.

Kevin Goodwin joined PIUR IMAGING as a strategic adviser in its June17,2026 announcement, helping US commercialization, fundraising strategy and OEM partnerships. He was the founding CEO of Sonosite and cofounder of EchoNous, according to the issuer’s biography. This advisory affiliation does not establish an individual cash investment.

Stacey Hong is named PIUR IMAGING EventMarketingManager and the issuer’s press contact in its June17,2026 strategic-adviser announcement. Her own public profile identifies the same company in Vienna. No executive, director or investor role is inferred from being a media contact.

Luc Ruysen is PIUR IMAGING’s GeneralManagerUSA in the current executive directory. His own company biography describes three decades of executive leadership and responsibility for US healthcare technology delivery. This source establishes the commercial role without inventing a statutory Austrian directorship or an exact joining day.

Robert Bauer is the current CTO and managing director of PIUR IMAGING, confirmed by its executive directory and legal imprint. His published role leads technology development for the company’s AI-assisted ultrasound software and acquisition platform. Product regulatory claims are limited to the specific cleared products and indications.

AURIMOD GmbH is a Vienna medical-technology company developing auricular vagus nerve stimulation for pain management. Its VIVO system delivers electrical pulses through small needle electrodes in the outer ear connected to a wearable battery-powered stimulator. The manufacturer identifies VIVO as a Class IIa medical device requiring physician prescription and application. Its VIVO Pal mobile app records patient-reported pain and wellbeing to support monitoring by patients and clinicians. Founded in 2015 as a spinout of TU Wien and the Medical University of Vienna, AURIMOD develops medical devices and conducts biomedical and clinical research on personalized neuromodulation.

Regenera is developing SpinoSave, an investigational regenerative therapy for spinal-cord injury that combines a patient’s own adipose-derived cells with a biodegradable hydrogel. The material is designed to be placed locally during surgery to provide a supportive environment for repair after injury. Its development combines biomaterials, tissue engineering and cell therapy; published research and regulatory designations support clinical translation, without establishing marketing authorization or approved clinical efficacy. Regenera GmbH is the Austrian group company headquartered in Vienna, registered in 2022. It holds the Swiss subsidiary Regenera SA and is the named sponsor of the European orphan designation for autologous adipose-derived stem cells intended to treat spinal-cord injury. The company reports an ILUM Tec seed investment announced in November 2022.

Regenera is developing SpinoSave, an investigational regenerative therapy for spinal-cord injury that combines a patient’s own adipose-derived cells with a biodegradable hydrogel. The material is designed to be placed locally during surgery to provide a supportive environment for repair after injury. Its development combines biomaterials, tissue engineering and cell therapy; published research and regulatory designations support clinical translation, without establishing marketing authorization or approved clinical efficacy. Regenera SA is the Lugano-based Swiss company in the Austrian–Swiss Regenera group, incorporated in 2021. Its parent’s published history says it became a wholly owned subsidiary of Regenera GmbH in July 2022. It participates in the group’s research and development and was incubated by the Università della Svizzera italiana Startup Centre. The Swiss company is legally distinct from the Austrian orphan-designation sponsor and direct ILUM investee.

Named with Regenera SA in the scientific organizer’s May 2026 edition of its June programme. The later programme lists only Zoe Giorgi; attendance and current employment are not inferred.

Frederik Bender is the current CEO and managing director of PIUR IMAGING, confirmed by its executive directory and Austrian legal imprint. He leads the company’s AI-assisted tomographic ultrasound platform and its commercial development. The actual legal directorship is distinguished from a personal investment; no personal check is inferred.

Bioengineer leading the Austrian company and chairing the Swiss subsidiary’s board.

Physician-scientist named as Regenera’s CMO on its own group team page.

Named with Regenera SA in the scientific organizer’s June 2026 programme. This is a dated published research affiliation, not an inferred employment title or director appointment.

PIUR IMAGING develops vendor-agnostic AI-assisted tomographic 3D ultrasound software and sensor-based acquisition systems, including PIUR tUS Infinity and PIUR tUS inside. Its workflows reconstruct ultrasound volumes, assist thyroid and nodule segmentation and measurements, and support vascular imaging applications. Clinicians review the proposed results; company workflow/performance claims are not independent clinical validation. The current Austrian legal entity is PIUR IMAGING GmbH, Handelsgericht Wien FN442623t, VAT ATU70008412, with managing directors Frederik Bender and Robert Bauer. The published brand timeline starts in 2014, while older financing releases say founded2015; the official Austrian registry independently records the legal company entry on November19,2015, distinct from the brand timeline. Current operating offices are Vienna, Munich and Cambridge, Massachusetts; a separately named US subsidiary in the terms does not establish that every office is the same legal corporation. FDA records independently establish Infinity K240036 clearance on September20,2024 and inside K250484 clearance on June30,2025 for their specific stated indications, including adult22+ thyroid assessment; these are not blanket approvals of every vascular, neurological or autonomous-AI use. The inside press-page February2025 metadata predates the actual FDA decision and is not used as the clearance date. MDR/CE/ISO statements are qualified as own-company claims where independent certificates have not been audited. The current executive directory names three leaders, complemented here by separately dated primary technical, marketing, advisory and founder affiliations rather than an asserted complete private payroll. Financing history includes aws Seedfinancing support identified only by year2015, a 2017 H2020 grant with exact EUR674276.40 company contribution, the EUR4.9million SeriesA aggregate announcedJuly2023, EUR5.6million growth capital announcedJuly9,2025 led by ACP, and a Companisto-reported EUR2415900 SeriesB crowdfunding/SPV tranche closedJuly15,2026 from612 investors. The earlier2022 counsel announcement and March first-close manager history belong to the qualified SeriesA cycle; an extra company round or EUR2.13million incremental raise is not invented. The crowdfunding amount is the reported campaign tranche rather than a verified whole-SeriesB total, and its platform is not asserted to have invested that amount from its own balance sheet. Fractional grant money cannot be represented by the integer-only Money schema, so exact cents remain in the source and the monetary field is NULL. No aws loan draw or 2020 guaranteed bank credit is inferred without proof.

Cardiac surgeon and biomedical researcher with experience in cardiovascular and translational research. Published as a member of the aws Preseed/Seedfinancing Deep Tech ethics council; this is an external expert role.

Medical-law and patient-safety researcher trained in law, with experience in ethics and healthcare rights. Published as a member of the aws Preseed/Seedfinancing Deep Tech ethics council; this is an external expert role.

Veterinary molecular-biology and biotechnology researcher with experience in biomedical genetics and animal research ethics. Published as a member of the aws Preseed/Seedfinancing Deep Tech ethics council; this is an external expert role.

Austria Wirtschaftsservice (aws) is the Austrian federal promotional bank and public economic-development financing agency. Its legal entity, Austria Wirtschaftsservice Gesellschaft mbH, is wholly owned by the Republic of Austria, registered in Vienna as FN227076k with VAT ATU55681202, and based at RechteWienzeile225,1120Vienna. Established under the aws Act with effect from January1,2002, it provides public loans, guarantees, grants, business-development services and mechanisms for mobilizing equity capital. Its technology programs support scalable Austrian companies in life sciences, AI and digital technologies, green technology and other deep-tech fields. Preseed and Seedfinancing provide early-stage public support and advice, while Quantum to Market supports commercialization of quantum technologies. Current DeepTech Seedfinancing is structured as a conditionally repayable grant; historical individual projects retain the instrument wording established by their own source. Its own case study confirms piur imaging received aws Seedfinancing in2015 for tomographic vascular ultrasound technology, without publishing a ticket or exact funding day. Co-directors BernhardSagmeister and GerfriedBrunner also administer the legally distinct statutory ERP-Fonds and serve the National Foundation for Research, Technology and Development through the agency’s public mandates. The separate aws Fondsmanagement GmbH manages the aws Gründungsfonds venture vehicles; agency grants or guarantees are not automatically equity investments by those funds. Annual program approvals, guaranteed volumes, government allocations and ERP assets are public-financing measures rather than LP fund closings. The current public directory lists119staff contacts, alongside executive management, a supervisory board and six published external DeepTech ethics-council advisers. This institution is distinct from Amazon Web Services.

Agnes Mlekusch is listed by Austria Wirtschaftsservice in its IP Management unit.

Alexandra Seidl is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Ali Suliman is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Industrie unit.

Andreas Schweigler is publicly named by Austria Wirtschaftsservice in its Supervisory Board Member — Staff Representative function. This verified institutional affiliation does not imply a personal investment.

Andrei Duduleanu is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Angela Siegling is listed by Austria Wirtschaftsservice in its IP Management unit.

Anna Weihs is listed by Austria Wirtschaftsservice in its Deep Technologies | Life Sciences unit.

Annemarie Wagner is listed by Austria Wirtschaftsservice in its Garantien für Gründungen und junge Unternehmen unit.

Anton Köszegi is listed by Austria Wirtschaftsservice in its Garantien für Industrie und Internationalisierung unit.

Anton Neunteufl is listed by Austria Wirtschaftsservice in its Garantien und Prämien für KMU unit.

Aridon Smajlaj is listed by Austria Wirtschaftsservice in its IP Management unit.

Arnold Reikerstorfer is listed by Austria Wirtschaftsservice in its Deep Technologies unit.

Astrid Mayer-Pail is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

Benjamin Delic is listed by Austria Wirtschaftsservice in its Deep Technologies unit.

Bernd Litzka is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Industrie unit.

Bernhard Sagmeister is co-managing director of Austria Wirtschaftsservice, jointly leading the Austrian federal promotional bank with Gerfried Brunner. The agency’s current management page also identifies him as an ERP-Fonds managing director and National Foundation for Research, Technology and Development board member through its statutory public mandates.

Bernhard Wipfel is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Industrie unit.

Bianca Anna Kahr is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Chiara Witzemann is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

Christa Bock is publicly named by Austria Wirtschaftsservice in its Supervisory Board Member function. This verified institutional affiliation does not imply a personal investment.

Christa Schlager is publicly named by Austria Wirtschaftsservice in its Supervisory Board Member function. This verified institutional affiliation does not imply a personal investment.

Christian Stein is listed by Austria Wirtschaftsservice in its Eigenkapital und Connecting Services unit.

Bioethics specialist trained in law, with experience in medical ethics administration and research ethics. Published as a member of the aws Preseed/Seedfinancing Deep Tech ethics council; this is an external expert role.

Christina Koch is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Christoph Pekarek is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

Claudia Hofinger is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

Claudia Sedlacek is listed by Austria Wirtschaftsservice in its Garantien für Gründungen und junge Unternehmen unit.

Clemens Zeiler is listed by Austria Wirtschaftsservice in its Deep Technologies unit.

Cornelia Habacher is listed by Austria Wirtschaftsservice in its Deep Technologies unit.

Cornelia Radlinger is listed by Austria Wirtschaftsservice in its IP Management unit.

Daniela Blutmager is listed by Austria Wirtschaftsservice in its Personal | Interne Services unit.

Dominica Schmid-Schmidsfelden is listed by Austria Wirtschaftsservice in its Eigenkapital und Connecting Services unit.

Dragana Iljic is listed by Austria Wirtschaftsservice in its Geschäftsführung - Büro B. Sagmeister unit.

Dusan Todorovic is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

Edith Schiller is publicly named by Austria Wirtschaftsservice in its Deputy Supervisory Board Chair function. This verified institutional affiliation does not imply a personal investment.

Elif Cicek is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Industrie unit.

Health-technology and digital-health specialist with a background in business development, telemedicine and innovation management. Published as a member of the aws Preseed/Seedfinancing Deep Tech ethics council; this is an external expert role.

Erika Köszegi-Lagally is listed by Austria Wirtschaftsservice in its Kredite | Kofinanzierungen unit.

Evelin Schnecker is listed by Austria Wirtschaftsservice in its Garantien für Industrie und Internationalisierung unit.

Eveline Birsak is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Gründungen und KMU unit.

Ezgi Okatan is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Industrie unit.

Florian Langmann-Frisch is publicly named by Austria Wirtschaftsservice in its Deputy Federal Finance Minister Commissioner function. This verified institutional affiliation does not imply a personal investment.

Georg Mikolasek is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

Georg Silber is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Industrie unit.

Gerd Zechmeister is listed by Austria Wirtschaftsservice in its IP Management unit.

Gerfried Brunner has been co-managing director of Austria Wirtschaftsservice since December 1, 2024, succeeding Edeltraud Stiftinger. He previously led the agency’s credit and co-financing division for eight years. He jointly oversees the public promotional bank with Bernhard Sagmeister and also serves, through the agency’s statutory mandates, as an ERP-Fonds managing director and National Foundation for Research, Technology and Development board member.

Hannah Lux is publicly named by Austria Wirtschaftsservice in its Supervisory Board Member function. This verified institutional affiliation does not imply a personal investment.

Hannes A. Schwetz is listed by Austria Wirtschaftsservice in its Deep Technologies unit.

Hans Peter Oswald is listed by Austria Wirtschaftsservice in its Garantien für Industrie und Internationalisierung unit.

Harald Kugler is listed by Austria Wirtschaftsservice in its Garantien für Industrie und Internationalisierung - KMU - Stabilisierung unit.

Helen Krüger is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

Isabella Meran-Waldstein is publicly named by Austria Wirtschaftsservice in its Supervisory Board Member function. This verified institutional affiliation does not imply a personal investment.

Jakob Seybold is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

James Friedenthal is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Industrie unit.

Jana Breyer is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Jana Schwab is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Jaqueline Hönigschnabel is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Industrie unit.

Jasmin Reisinger is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

Jenny Bors is listed by Austria Wirtschaftsservice in its IP Management unit.

Johann Kreuter is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Industrie unit.

Johannes Raymann is listed by Austria Wirtschaftsservice in its Eigenkapital und Connecting Services unit.

Johannes Schellnegger is listed by Austria Wirtschaftsservice in its Eigenkapital und Connecting Services unit.

Judith Hofstätter is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Gründungen und KMU unit.

Julia Heißinger is listed by Austria Wirtschaftsservice in its Garantien und Prämien für KMU unit.

Julia Maria Schanderl is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Julia Wilflingseder is listed by Austria Wirtschaftsservice in its Deep Technologies unit.

Jürgen Natter is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

Kaan Aksu is listed by Austria Wirtschaftsservice in its Investitionsprämie unit.

Karin Kofler is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Gründungen und KMU unit.

Karin Winkelbauer is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Karl Biedermann is listed by Austria Wirtschaftsservice in its Deep Technologies unit.

Karl Schiller is listed by Austria Wirtschaftsservice in its Deep Technologies unit.

Katharina Lichtenecker is listed by Austria Wirtschaftsservice in its Garantien und Prämien für KMU unit.

Katrin Pacholet is listed by Austria Wirtschaftsservice in its Geschäftsführung - Büro G. Brunner unit.

Kerstin Derntl is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Industrie unit.

Kurt Leutgeb is listed by Austria Wirtschaftsservice in its Garantien | Eigenkapital - Leiter Geschäftsfeld unit.

Leyla Gharizade is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Industrie unit.

Liesa Doppler is listed by Austria Wirtschaftsservice in its Deep Technologies unit.

Lisa-Marie Ettenauer is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Luc Pfefferkorn is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Gründungen und KMU unit.

Manfred Lampl is listed by Austria Wirtschaftsservice in its IP Management unit.

Maria Hüttmair is listed by Austria Wirtschaftsservice in its Garantien und Prämien für KMU unit.

Maria Steindl-Köck is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

Markus Kottek-Pasterk is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

Martin Motal is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Martina Eigler is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Gründungen und KMU unit.

Matthias Bischof is listed by Austria Wirtschaftsservice in its Unternehmenskommunikation | Pressestelle unit.

Melanie Vöhringer is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Industrie unit.

Men Jia Qiu is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

Milena Makrisevic is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Miriam Fuhrmann is publicly named by Austria Wirtschaftsservice in its Supervisory Board Member function. This verified institutional affiliation does not imply a personal investment.

Monika Bednarik-Belan is listed by Austria Wirtschaftsservice in its Garantien für Industrie und Internationalisierung unit.

Monika Pollack is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Industrie unit.

Monika Vuong is listed by Austria Wirtschaftsservice in its IP Management unit.

Moritz Dominik Weinhofer is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

My Yen Lau is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

Neshat Akbari is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Nicolas Mayerhofer is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

Niels Mitschke is listed by Austria Wirtschaftsservice in its IP Management unit.

Noel Velten is listed by Austria Wirtschaftsservice in its Garantien für Industrie und Internationalisierung unit.

Nordin Sabovic is listed by Austria Wirtschaftsservice in its Eigenkapital und Connecting Services unit.

Olena Kharkhun is listed by Austria Wirtschaftsservice in its Garantien für Industrie und Internationalisierung unit.

Paul Ullmann is listed by Austria Wirtschaftsservice in its Deep Technologies unit.

Peter Kühne is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Peter Swiatloski is publicly named by Austria Wirtschaftsservice in its Supervisory Board Member — Staff Representative function. This verified institutional affiliation does not imply a personal investment.

Petra Riegler is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Rafet Ibra is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Industrie unit.

Raffael Johannes Wolff is listed by Austria Wirtschaftsservice in its Deep Technologies unit.

Ralf Kronberger is publicly named by Austria Wirtschaftsservice in its Supervisory Board Member function. This verified institutional affiliation does not imply a personal investment.

Raphael Kletzmayr is listed by Austria Wirtschaftsservice in its Garantien für Industrie und Internationalisierung unit.

Regina Weinmüllner is listed by Austria Wirtschaftsservice in its Deep Technologies unit.

Sabine Jaroschka is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Sabine Pümpel is listed by Austria Wirtschaftsservice in its Kredite | Kofinanzierungen unit.

Sabrina Tonner is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Sebastian Schmid is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Industrie unit.

Sonja Polan is listed by Austria Wirtschaftsservice in its IP Management unit.

Sophia Lang is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Sophie Lothaller is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Soren Charareh is listed by Austria Wirtschaftsservice in its Deep Technologies unit.

Stefan Krahulec is listed by Austria Wirtschaftsservice in its Deep Technologies unit.

Stefan Langthaler is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Stefan Rechberger is publicly named by Austria Wirtschaftsservice in its Federal Finance Minister Commissioner function. This verified institutional affiliation does not imply a personal investment.

Stefan Zeiler is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Stefanie Bruckler is listed by Austria Wirtschaftsservice in its Deep Technologies unit.

Stella Mitsche is listed by Austria Wirtschaftsservice in its Kreditmanagement und Kofinanzierungen für Industrie unit.

Susanne Liedmair is listed by Austria Wirtschaftsservice in its Entrepreneurship unit.

Tanja Lässig is publicly named by Austria Wirtschaftsservice in its Supervisory Board Member function. This verified institutional affiliation does not imply a personal investment.

Tanja Spennlingwimmer is listed by Austria Wirtschaftsservice in its IP Management | Deep Technologies | Entrepreneurship - Leiterin Geschäftsfeld unit.

Thomas Blöch is listed by Austria Wirtschaftsservice in its Unternehmenskommunikation unit.

Thomas Steiner is publicly named by Austria Wirtschaftsservice in its Supervisory Board Member function. This verified institutional affiliation does not imply a personal investment.

Thomas Uher is publicly named by Austria Wirtschaftsservice in its Supervisory Board Chair function. This verified institutional affiliation does not imply a personal investment.

Vanja Bernhauer is listed by Austria Wirtschaftsservice in its IP Management unit.

Walter Koppensteiner is listed by Austria Wirtschaftsservice in its IP Management unit.

Wassilis Laitsos is listed by Austria Wirtschaftsservice in its Garantien für Industrie und Internationalisierung unit.

Wilhelm Hantsch-Linhart is listed by Austria Wirtschaftsservice in its Garantien für Industrie und Internationalisierung unit.

Biomedical-imaging researcher trained in electrical engineering and medical physics, with experience in optical imaging and biomedical engineering. Published as a member of the aws Preseed/Seedfinancing Deep Tech ethics council; this is an external expert role.

Wolfgang Schönecker is listed by Austria Wirtschaftsservice in its Investitionsprämie unit.

Wolfgang Sendner is listed by Austria Wirtschaftsservice in its Eigenkapital unit.

Joe Wu was DHVC’s director of operations in the official August2018directory. His responsibilities included financial reporting and operations, drawing on public-accounting, investment-company and tax experience. Earlier roles included FormationGroup,SalientPartners andErnstAndYoung. This affiliation is historical, not a currentemploymentclaim.

Yulei Wang was a DHVC senior associate in the official August2018directory. Her published work combined biotechnology, data and blockchain, with interests in computational drug discovery and disease detection. The archived biography describes training in biology and statistics atHarvard. CurrentDHVCemployment is unconfirmed.

Brendan Tobin was a DHVC associate in the official August2018directory. His prior experience included CreditKarma andSamsungResearchAmerica, with work on technology commercialisation, machine learning, computer vision and investing. He studied management science and engineering atStanford and materials science atArizona. This role is historical.

Callie Wang was a DHVC associate in the official August2018directory, focused on blockchain, consumer technology and fintech. Her earlier work included business development and market research in startup businesses. She studied marketing atNYU and accounting atSunYatSenUniversity. CurrentDHVCemployment is unconfirmed.

Rachel Wan was a DHVC director in the firm’s official August2018directory. Her published work covered investor relations, financing and portfolio support. Earlier experience included InvestmentTechnologyGroup; she studied finance atLSE and information science atIndianaUniversity. CurrentDHVCemployment is unconfirmed.

Dovey Wan was a DHVC managing director in the official August2018archived directory. Her historical investing covered artificial intelligence, mobility, fintech and blockchain. Before venture investing she worked in product and analytics at eBay; she studied information systems atCarnegieMellon. This affiliation is historical, not independently established as current2026employment.

Fabio Mondini appears in Idinvest Partners’ August2020 primary directory as Venture Partner. The publisher separately classified this as an external strategic or investment advisory affiliation, rather than full-time operating staff. The named historical role is distinguished from the preserved later Eurazeo affiliations. Idinvest became Eurazeo Investment Manager and was subsequently absorbed into Eurazeo Global Investor. Joining and departure days and unpublished prior career or education details are not inferred.